WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2005113606) FGF-21 FUSION PROTEINS
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/2005/113606    International Application No.:    PCT/US2005/015111
Publication Date: 01.12.2005 International Filing Date: 02.05.2005
IPC:
C07K 14/50 (2006.01), C12N 15/62 (2006.01), A61K 38/18 (2006.01), A61P 3/04 (2006.01), A61P 3/10 (2006.01)
Applicants: ELI LILLY AND COMPANY [US/US]; Lilly Corporate Center Indianapolis, Indiana 46285 (US) (For All Designated States Except US).
GLAESNER, Wolfgang [DE/US]; (US) (For US Only).
MILLICAN, Rohn, Lee, Junior [US/US]; (US) (For US Only).
TIAN, Yu [CN/US]; (US) (For US Only).
TSCHANG, Sheng-Hung, Rainbow [US/US]; (US) (For US Only)
Inventors: GLAESNER, Wolfgang; (US).
MILLICAN, Rohn, Lee, Junior; (US).
TIAN, Yu; (US).
TSCHANG, Sheng-Hung, Rainbow; (US)
Agent: APELGREN, Lynn, D.; ELI LILLY AND COMPANY, P. O. Box 6288, Indianapolis, Indiana 46206-6288 (US)
Priority Data:
60/570,098 13.05.2004 US
Title (EN) FGF-21 FUSION PROTEINS
(FR) PROTEINES DE FUSION FGF-21
Abstract: front page image
(EN)The invention provides specific FGF-21 compounds fused to specific IgG4-Fc or HSA derivatives resulting in fusion proteins that are biologically active with an extended elimination half-life and a slower clearance. These FGF-21 compound fusion proteins and compositions are useful in treating type 2 diabetes, obesity, and metabolic syndrome.
(FR)L'invention fournit des composés spécifiques FGF-21 fusionnés aux dérivés spécifiques IgG4-Fc ou HSA résultant dans des protéines de fusion qui sont biologiquement actives avec une demi-vie et une clairance plus lente. Ces protéines de fusion de composés et de compositions sont utiles dans le traitement du diabète de type 2, de l'obésité et du syndrome métabolique
Designated States: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
African Regional Intellectual Property Organization (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)